Skip to content

Blood Transfusion Management in Patients With Mitral Valve Replacement in China

Establishment of AI Prediction Model of Blood Transfusion Management in Patients With Mitral Valve Replacement

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03885570
Enrollment
2000
Registered
2019-03-21
Start date
2019-09-16
Completion date
2021-12-31
Last updated
2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Transfusion Complication, Mitral Valve Replacement, Transfusion Reaction

Keywords

mitral valve replacement, Predictive Model, Blood Transfusion, Perioperative period

Brief summary

The evaluation uses ΔHb as an independent factor combined with artificial intelligence (AI) to predict its impact on the prognosis and blood transfusion of patients undergoing cardiac surgery, thereby guiding perioperative clinical blood use and improving patient prognosis.

Detailed description

1. Select 8 hospitals to form a multi-center team, and enter the keyword mitral valve replacement in the case system of 8 hospitals to collect information on 2000 heart surgery patients. 2. Mainly collect information on preoperative, intraoperative and postoperative test indexes (blood routine, liver and kidney function, coagulation function, blood gas), cardiac color Doppler, blood transfusion and prognosis of patients undergoing cardiac surgery, using statistical methods for analysis. Identify key observations. 3. Gradually incorporate and exclude data, and use statistical methods to conduct preliminary analysis on the collected data. The AI prediction model was established by machine learning algorithm to predict intraoperative blood transfusion, verify the specificity and sensitivity of the blood transfusion prediction model, and scientifically guide clinical blood use.

Interventions

PROCEDUREMitral valve replacement

Blood transfusion

Sponsors

Second Xiangya Hospital of Central South University
CollaboratorOTHER
Chinese Academy of Medical Sciences, Fuwai Hospital
CollaboratorOTHER
The Affiliated Hospital Of Southwest Medical University
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
Zhejiang Provincial People's Hospital
CollaboratorOTHER
Beijing Aerospace General Hospital
CollaboratorOTHER
The Third Xiangya Hospital of Central South University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing mitral valve replacement surgery; 2. Age 18-75 years old; 3. 48h biochemical indicators before surgery, blood general indicators, coagulation indicators are complete.

Exclusion criteria

1. Lack of necessary tests and patient test information is not detailed, blood transfusion information is not detailed; 2. The blood transfusion information is not detailed in the same period as other cardiac operations (such as aortic valve surgery, coronary artery bypass grafting, etc.), but the tricuspid valvuloplasty is not ruled out at the same time; 3. Heart surgery or emergency surgery again.

Design outcomes

Primary

MeasureTime frameDescription
Mortalitythrough study completion, an average of 2 yearThe mortality during and after hospitalization
Intraoperative blood transfusionthrough study completion, an average of 1 yearThe amount of intraoperative blood component input

Countries

China

Contacts

Primary ContactRong Gui, Ph.D
aguirong@163.com13975199279
Backup ContactHaiye Jiang, M.Med.
1972692495@qq.com13974873361

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026